SPOTLIGHT: Astellas investigates patient death

Japan's Astellas Pharma is investigating the death of a 76-year-old patient in a trial of YM 311, an experimental anemia drug. The patient was taking 10 different medications besides YM 311, but a doctor has indicated that the death may be linked to the experimental drug. Astellas is in discussions with the FDA. Release (.pdf)

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.